Baltimore Capital Management Inc. purchased a new stake in shares of AbbVie Inc. (NYSE:ABBV) during the first quarter, according to its most recent 13F filing with the SEC. The firm purchased 11,050 shares of the company’s stock, valued at approximately $720,000.

Other large investors have also modified their holdings of the company. Canada Pension Plan Investment Board raised its position in AbbVie by 6.5% in the first quarter. Canada Pension Plan Investment Board now owns 3,151,990 shares of the company’s stock valued at $205,384,000 after buying an additional 193,410 shares in the last quarter. US Bancorp DE raised its position in AbbVie by 0.3% in the first quarter. US Bancorp DE now owns 2,947,561 shares of the company’s stock valued at $192,064,000 after buying an additional 9,289 shares in the last quarter. Rhumbline Advisers raised its position in AbbVie by 0.3% in the first quarter. Rhumbline Advisers now owns 2,455,314 shares of the company’s stock valued at $159,988,000 after buying an additional 7,181 shares in the last quarter. Great West Life Assurance Co. Can raised its position in AbbVie by 0.6% in the first quarter. Great West Life Assurance Co. Can now owns 1,642,457 shares of the company’s stock valued at $106,949,000 after buying an additional 9,709 shares in the last quarter. Finally, First Trust Advisors LP raised its position in AbbVie by 11.8% in the first quarter. First Trust Advisors LP now owns 1,367,680 shares of the company’s stock valued at $89,118,000 after buying an additional 144,231 shares in the last quarter. Hedge funds and other institutional investors own 68.27% of the company’s stock.

Shares of AbbVie Inc. (ABBV) traded down 0.1069% during trading on Tuesday, hitting $73.2416. 429,016 shares of the stock traded hands. The stock has a 50-day moving average of $71.65 and a 200 day moving average of $67.49. AbbVie Inc. has a 1-year low of $55.06 and a 1-year high of $75.04. The company has a market cap of $116.75 billion, a P/E ratio of 18.0132 and a beta of 1.50.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, July 28th. The company reported $1.42 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.40 by $0.02. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. The business had revenue of $6.94 billion during the quarter, compared to the consensus estimate of $6.93 billion. During the same period in the prior year, the company posted $1.26 EPS. The firm’s revenue for the quarter was up 7.6% compared to the same quarter last year. On average, equities research analysts predict that AbbVie Inc. will post $5.52 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, August 15th. Shareholders of record on Friday, July 14th were paid a $0.64 dividend. The ex-dividend date was Wednesday, July 12th. This represents a $2.56 annualized dividend and a yield of 3.49%. AbbVie’s payout ratio is 62.90%.

WARNING: “Baltimore Capital Management Inc. Takes Position in AbbVie Inc. (ABBV)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/29/baltimore-capital-management-inc-takes-position-in-abbvie-inc-abbv.html.

ABBV has been the topic of several recent analyst reports. Zacks Investment Research lowered shares of AbbVie from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. Vetr raised shares of AbbVie from a “buy” rating to a “strong-buy” rating and set a $74.38 target price for the company in a report on Monday, May 8th. Jefferies Group LLC reaffirmed a “buy” rating on shares of AbbVie in a report on Friday, May 26th. Credit Suisse Group reaffirmed a “hold” rating and set a $65.00 target price on shares of AbbVie in a report on Wednesday, June 7th. Finally, Cowen and Company set a $70.00 target price on shares of AbbVie and gave the stock a “hold” rating in a report on Sunday, July 30th. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $76.02.

In other AbbVie news, Chairman Richard A. Gonzalez sold 193,131 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $71.00, for a total value of $13,712,301.00. Following the completion of the transaction, the chairman now directly owns 469,623 shares in the company, valued at approximately $33,343,233. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Richard A. Gonzalez sold 65,861 shares of the company’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $71.00, for a total value of $4,676,131.00. Following the completion of the transaction, the chief executive officer now owns 342,353 shares of the company’s stock, valued at $24,307,063. The disclosure for this sale can be found here. Insiders sold a total of 490,491 shares of company stock valued at $34,684,639 over the last 90 days. 0.23% of the stock is currently owned by corporate insiders.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Stock Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related stocks with our FREE daily email newsletter.